Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts


Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Patrick Andrew Brown, M.D.

Headshot of Patrick Andrew Brown
  • Director, Pediatric Leukemia Program
  • Professor of Oncology


Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Blood Cancers, Chronic Myeloid Leukemia (CML), Hodgkin's Disease, Leukemia, Lymphoma, Medical Oncology, Myelodysplastic Syndromes (MDS), Non-Hodgkin's Lymphoma (NHL), Pediatric Oncology more

Request an Appointment

Insurance Information

Main Phone


Outside of Maryland

Request Appointment

International Patients

Request Appointment


The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-955-8751
1800 Orleans St.
The Charlotte R. Bloomberg Children's Center Building, 11th Floor
Baltimore, MD 21287 map


Dr. Brown's research is focused on developing new therapies for childhood leukemia. Leukemia (cancer of the blood-forming cells in the bone marrow) is the most common form of cancer in children. While great improvements have been made in the rates of cure for children with leukemia overall, certain types of childhood leukemia continue to have very low cure rates with the best known treatments, and new treatments are clearly needed for these children. Furthermore, the standard treatments for childhood leukemia (intensive chemotherapy and, in some cases, bone marrow transplantation) can cause significant, and not uncommonly debilitating, acute and late complications. New treatments that are just as effective against the leukemia, but less toxic to the patient, could vastly improve the outlook for this disease. Recent advances in cancer research have enabled the discovery of genetic changes (mutations) which cause certain types of cancer, and subsequently to drugs which can target these mutated genetic pathways. These targeted drugs have the potential to be more effective and less toxic than the standard treatments.

Dr. Brown's lab has found that a gene called FLT3 (which was initially discovered by Dr. Brown's mentor, Dr. Don Small) is particularly important in the types of childhood leukemia with low cure rates. Several FLT3-targeted drugs (inhibitors) are being developed. Since leukemia is not caused by a single mutation, but rather by several mutations occurring together in the same cells, combinations of drugs are needed. Dr. Brown's lab has identified promising combinations of standard chemotherapy drugs and FLT3 inhibitors that can work together to more effectively kill leukemia cells. Based on this work, Dr. Brown, a member of the Johns Hopkins Kimmel Cancer Center, is now leading the first clinical trials of a FLT3 inhibitor combined with chemotherapy in children with leukemia through the Children's Oncology Group international network. In conjunction with these clinical trials, Dr. Brown's lab is performing further experiments in the laboratory to help optimize dosing, to develop a test that can be used to predict which patients are most likely to benefit from the new drugs, and to determine how leukemia cells are able to survive despite treatment.

Hopefully, these efforts will result in significant improvements in the cure rates for these children.

Dr. Brown's lab continues to investigate other ways to improve the treatment of childhood leukemia by developing therapies that can overcome resistance to chemotherapy, and, unlike chemotherapy, are selectively targeted to the mutations that cause leukemia. The success of these efforts depends in large part on the amazing work being done by our colleagues and collaborators here at Hopkins and elsewhere, and by our post-doctoral fellows and technicians who have joined the lab and bring new ideas, energy and a willingness to do the hard work that makes such advances possible. more


  • Director, Pediatric Leukemia Program
  • Professor of Oncology
  • Professor of Pediatrics

Departments / Divisions

Centers & Institutes



  • MD; Medical University of South Carolina College of Medicine (1998)


  • Pediatrics; Johns Hopkins University School of Medicine (2001)


  • Pediatric Oncology; Johns Hopkins University School of Medicine (2004)

Board Certifications

  • American Board of Pediatrics (Pediatric Hematology-Oncology) (2006)

Research & Publications

Clinical Trial Keywords

Acute Lymphoblastic Leukemia (ALL)

Selected Publications

Cooper TM, Sison EA, Baker SD, Li L, Ahmed A, Trippett T, Gore L, Macy ME, Narendran A, August K, Absalon MJ, Boklan J, Pollard J, Magoon D, Brown P. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03). Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26414. Epub 2017 Apr 14.

Brown P. Blinatumomab for MRD+ B-ALL: the evidence strengthens. Blood. 2018 Apr 5;131(14):1497-1498. doi: 10.1182/blood-2018-02-830364.

Brown P, Shah B. Emerging Treatment Options for Acute Lymphoblastic Leukemia: Focus on CAR T-Cell Therapy. J Natl Compr Canc Netw. 2018 May;16(5S):651-655. doi: 10.6004/jnccn.2018.0048. PMID: 29784748 [PubMed - in process]

Gupta S, Devidas M, Loh ML, Raetz EA, Chen S, Wang C, Brown P, Carroll AJ, Heerema NA, Gastier-Foster JM, Dunsmore KP, Larsen EC, Maloney KW, Mattano LA Jr, Winter SS, Winick NJ, Carroll WL, Hunger SP, Borowitz MJ, Wood BL. Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). Leukemia. 2018 Jun;32(6):1370-1379. doi: 10.1038/s41375-018-0039-7. Epub 2018 Feb 23.

Ogba N, Arwood NM, Bartlett NL, Bloom M, Brown P, Brown C, Budde EL, Carlson R, Farnia S, Fry TJ, Garber M, Gardner RA, Gurschick L, Kropf P, Reitan JJ, Sauter C, Shah B, Shpall EJ, Rosen ST. Chimeric Antigen Receptor T-Cell Therapy. J Natl Compr Canc Netw. 2018 Sep;16(9):1092-1106. doi: 10.6004/jnccn.2018.0073.

Activities & Honors

Professional Activities

  • Executive steering committee, Acute Lymphoblastic Leukemia 
  • Executive steering committee, Myeloid Disorders Committee
  • , Childrens Oncology Group
  • , POETIC pediatric phase I consortium
Is this you? Edit Profile
back to top button